Research Analysts Offer Predictions for CRSP FY2025 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of CRISPR Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($5.08) for the year. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.13) per share.

Several other equities analysts have also weighed in on CRSP. Bank of America reduced their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Barclays reduced their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Wednesday, November 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $78.38.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP traded down $1.30 during mid-day trading on Wednesday, reaching $42.90. The company's stock had a trading volume of 513,677 shares, compared to its average volume of 1,920,295. The company's fifty day simple moving average is $44.43 and its two-hundred day simple moving average is $47.88. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10. The stock has a market cap of $3.66 billion, a P/E ratio of -15.10 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same period last year, the company earned ($1.41) EPS.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the sale, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. The trade was a 13.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Perigon Wealth Management LLC increased its holdings in shares of CRISPR Therapeutics by 11.4% in the 4th quarter. Perigon Wealth Management LLC now owns 16,757 shares of the company's stock valued at $675,000 after acquiring an additional 1,717 shares during the last quarter. KBC Group NV boosted its position in CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after purchasing an additional 57,696 shares during the period. PFG Investments LLC boosted its position in CRISPR Therapeutics by 9.9% during the 4th quarter. PFG Investments LLC now owns 10,603 shares of the company's stock valued at $417,000 after purchasing an additional 952 shares during the period. Hedges Asset Management LLC boosted its position in CRISPR Therapeutics by 5.1% during the 4th quarter. Hedges Asset Management LLC now owns 24,350 shares of the company's stock valued at $958,000 after purchasing an additional 1,188 shares during the period. Finally, MCF Advisors LLC acquired a new position in CRISPR Therapeutics during the 4th quarter valued at approximately $80,000. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.